Traws Pharma, Inc. (NASDAQ:TRAW) Stock Rated “Reduce” by Sell-Side Analysts

Traws Pharma, Inc. (NASDAQ:TRAW) has been assigned a consensus recommendation of “Reduce” from the five research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $1.00.

A number of equities research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price objective on shares of Traws Pharma in a research report on Tuesday, August 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Traws Pharma in a report on Wednesday, August 26th.

Traws Pharma Trading Down 2.5%

TRAW stock opened at $0.37 on Friday. Traws Pharma has a 1-year low of $0.36 and a 1-year high of $3.23. The firm has a fifty day moving average price of $0.52 and a two-hundred day moving average price of $0.89.

Traws Pharma (NASDAQ:TRAW) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.18. Equities research analysts expect that Traws Pharma will post -1.20 EPS for the current fiscal year.

Traws Pharma Company Profile

Traws Pharma, Inc (NASDAQ: TRAW) is a clinical-stage biopharmaceutical company developing medicines for viral infections and cancer. The company’s research and development programs are focused primarily on oral antiviral therapies for respiratory viruses, including influenza and COVID-19.

Traws Pharma’s antiviral pipeline includes tivoxavir marboxil, an investigational treatment designed to inhibit viral replication in influenza A, along with additional antiviral candidates targeting respiratory infections.